Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simvastatin Addition for Recent-onset Schizophrenia
NCT01999309Phase 3Completed
- Start
- Oct 2013
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia, schizoaffective disorder, schizophreniform disorder and 1 more comparing Simvastatin with Placebo (2 arms). Primary endpoint: Total symptom severity (Positive and Negative Syndrome Scale) at 12 months. Started Oct 2013; status: completed.
02
Drugs
simvastatin
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorderpsychosis
Beyond the preview
Go deeper on NCT01999309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999309.